Business
ArriVent is a clinical-stage oncology company led by firmonertinib for EGFR-mutated non-small cell lung cancer and additional antibody drug conjugate work.
ArriVent remained pre-revenue, with a wider loss and weaker free cash flow, while equity rose to $307.2M.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical oncology pipelineNote
- Revenue — No revenue taggedNote
- Losses — Net loss widened to $166.3MWatch
- Cash — FCF fell to -$160.6MWatch
- Capital — Equity rose 19.2%OK
- Insiders — 0 buys / 1 sellWatch
- Accounting — Forensic screen unavailableNote
Leadership changes
From ArriVent BioPharma, Inc.'s own filings, the day they're filed.
- Merdad Parsey · director · appointmenteff. 2025-04-28
- Carl L. Gordon · directors · departureeff. 2025-04-23
- John Hohneker · Director · appointmenteff. 2024-05-16
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-05-11
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ArriVent BioPharma, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.